Add to Calendar 3/27/2019 8:15:00 AM 3/28/2019 2:30:00 PM 2019 Annual Meeting: State of Possible Conference
This year’s Annual Meeting is now the State of Possible Conference where we'll celebrate what’s possible in our industry and for patients today that wasn’t five or 10 years ago. The two-day event will draw over 600 industry leaders from Massachusetts and beyond to debate the most pressing challenges facing the life sciences to ensure we can continue this incredible success. Attendees will hear from the brightest minds through keynotes, panel discussions and 15-minute Possible Talks, inspiring and engaging content in the style of a TED Talk. We'll also have a networking reception, the State of Possible Celebration, immediately following Day 1 of the conference, where we'll have great food, drinks, a DJ. Attendees will also have access to the exhibits at the Museum of Science. Join us as we celebrate the State of Possible!
 

If you haven’t attended our Annual Meeting before, it is the premier east coast life sciences conference and this year’s event is better than ever. With speakers like Katrine Bosley, John Maraganore, Jeremy Levin, George Church, and more, we have some of the brightest names in biotech talking about the issues impacting our industry. See our incredible lineup of speakers and topics below. Online registration closes at noon on Tuesday, March 26th. Walk-in registrations will be available on-site. 

 Royal Sonesta Boston, 40 Edwin Land Blvd Cambridge MA 02142
Katrine Bosley is the Chief Executive Officer of Editas Medicine Prior to joining Editas, Katrine was an Entrepreneur-in-Residence at The Broad Institute, a biomedical and genomic research center, and before that, she was the CEO of Avila Therapeutics (acquired by Celgene). Katrine was also Vice President, Business Development at Adnexus Therapeutics and then Vice President, Strategic Operations after Adnexus’ acquisition by Bristol-Myers Squibb. Earlier, Katrine held several positions at Biogen in Business Development, Commercial Operations, and Portfolio Strategy and was part of the healthcare team at the venture firm Highland Capital Partners. She is a graduate of Cornell University. In addition to her role at Editas, Katrine currently serves as Chairman of the Board of Genocea Biosciences (NASDAQ: GNCA) and is a member of the Board of Directors of Galapagos NV (EURONEXT and NASDAQ: GLPG), of BIO – the Biotechnology Innovation Organization, and of Massachusetts Eye and Ear.

Brought to you by